Literature DB >> 19508172

Targeting the mevalonate pathway for improved anticancer therapy.

G Fritz1.   

Abstract

The mevalonate pathway is important for the generation of isoprene moieties thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho proteins at their C-terminal CAAX-box is essential for their correct intracellular localization and function. Therefore, pharmacological inhibition of the isoprene metabolism is anticipated to impact the manifold biological functions attributed to Ras/Rho proteins. Here, the pros and cons of compounds that interfere with the mevalonate pathway for cancer treatment are summarized and discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508172     DOI: 10.2174/156800909789057033

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  25 in total

1.  Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae.

Authors:  Scott T Lefurgy; Sofia B Rodriguez; Chan Sun Park; Sean Cahill; Richard B Silverman; Thomas S Leyh
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

2.  Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.

Authors:  Annemarie Greife; Jitka Tukova; Christine Steinhoff; Simon D Scott; Wolfgang A Schulz; Jiri Hatina
Journal:  Tumour Biol       Date:  2015-01-08

Review 3.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

4.  Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2011-12       Impact factor: 4.677

5.  Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.

Authors:  Gabriella Misso; Manuela Porru; Antonella Stoppacciaro; Maria Castellano; Federica De Cicco; Carlo Leonetti; Daniele Santini; Michele Caraglia
Journal:  Cancer Biol Ther       Date:  2012-09-18       Impact factor: 4.742

Review 6.  Therapeutic targeting of the p53 pathway in cancer stem cells.

Authors:  Varun V Prabhu; Joshua E Allen; Bo Hong; Shengliang Zhang; Hairong Cheng; Wafik S El-Deiry
Journal:  Expert Opin Ther Targets       Date:  2012-09-24       Impact factor: 6.902

7.  Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.

Authors:  R A Mans; L L McMahon; L Li
Journal:  Neuroscience       Date:  2011-12-13       Impact factor: 3.590

8.  Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.

Authors:  Stefanie C Huelsenbeck; Anne Schorr; Wynand P Roos; Johannes Huelsenbeck; Christian Henninger; Bernd Kaina; Gerhard Fritz
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

9.  Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae.

Authors:  Takashi Kudoh; Chan Sun Park; Scott T Lefurgy; Meihao Sun; Theodore Michels; Thomas S Leyh; Richard B Silverman
Journal:  Bioorg Med Chem       Date:  2009-12-24       Impact factor: 3.641

Review 10.  Exploiting synthetic lethal interactions for targeted cancer therapy.

Authors:  H Christian Reinhardt; Hai Jiang; Michael T Hemann; Michael B Yaffe
Journal:  Cell Cycle       Date:  2009-10-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.